Clinical Roundup Tecvayli demonstrates potential in MM Johnson & Johnson announced new frontline data featuring Tecvayli (teclistamab-cqyv) from two investigational studies in patients with newly diagnosed multiple myeloma in induction and maintenance settings. December 13, 2024Vol.50 No.46